In summary, we have identified hexavalent TRAIL receptor agonist IZI1551 to be superior in actively inducing cell death in mutBRAF melanoma compared to conventional trimeric TRAIL but also compared to specific targeted mutBRAF kinase inhibitors as used in the clinic. Here, TNFSF10 is linked to melanoma.